Vivani Medical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vivani Medical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $4.00M | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $8.90M | Mar 16, 2017 |
| FY2016 | Dec 31, 2014 | $3.40M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $1.57M | Mar 11, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $130.0K | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $500.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $373.0K | Mar 16, 2021 |
| FY2020 | Sep 30, 2019 | $108.0K | Mar 16, 2021 |
| FY2020 | Jun 30, 2019 | $349.0K | Mar 16, 2021 |
| FY2020 | Mar 31, 2019 | $397.0K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $167.0K | Mar 19, 2020 |
| FY2019 | Sep 30, 2018 | $462.0K | Mar 19, 2020 |
| FY2019 | Jun 30, 2018 | $1.07M | Mar 19, 2020 |
| FY2019 | Mar 31, 2018 | $308.0K | Mar 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.61M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($23.49M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($25.65M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($13.89M) | Mar 26, 2024 |
| FY2021 | Dec 31, 2021 | ($1.28M) | Mar 29, 2022 |
| FY2021 | Sep 30, 2021 | ($2.50M) | Mar 29, 2022 |
| FY2021 | Jun 30, 2021 | ($2.29M) | Mar 29, 2022 |
| FY2021 | Mar 31, 2021 | ($2.84M) | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | ($1.29M) | Mar 29, 2022 |
| FY2021 | Sep 30, 2020 | ($1.60M) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.56M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($24.68M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($26.97M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($21.24M) | Mar 26, 2024 |
| FY2021 | Dec 31, 2021 | ($1.29M) | Mar 29, 2022 |
| FY2021 | Sep 30, 2021 | ($2.50M) | Mar 29, 2022 |
| FY2021 | Jun 30, 2021 | ($2.30M) | Mar 29, 2022 |
| FY2021 | Mar 31, 2021 | ($2.84M) | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | ($1.27M) | Mar 29, 2022 |
| FY2021 | Sep 30, 2020 | ($1.60M) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.13M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.75M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $16.97M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.17M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $11.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.84M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $13.14M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $10.01M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $7.89M | Mar 19, 2019 |
| FY2018 | Dec 31, 2016 | $5.35M | Mar 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.32M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($20.79M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($23.70M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.79M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($10.95M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($16.82M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($27.63M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($29.81M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($23.95M) | Mar 19, 2019 |
| FY2018 | Dec 31, 2016 | ($25.07M) | Mar 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $556.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $887.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $338.0K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $572.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $330.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $493.0K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $163.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $265.0K | Mar 19, 2019 |
| FY2018 | Dec 31, 2016 | $490.0K | Mar 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.39M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $41.56M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $45.80M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $51.13M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $5.45M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.46M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $16.60M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $10.68M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $14.50M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | $16.81M | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.66M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $23.95M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $25.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.82M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $2.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.13M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $9.32M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $7.60M | Mar 19, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.73M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.61M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $20.76M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $44.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $2.47M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.95M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $7.28M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $3.08M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $7.88M | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $11.15M | Mar 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($148.53M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($121.92M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($98.44M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($72.79M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($58.90M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($319.66M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($304.78M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($269.47M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($234.38M) | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | ($205.86M) | Mar 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.23M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.35M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $20.65M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $45.08M | Mar 26, 2024 |
| FY2021 | Dec 31, 2021 | $69.59M | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $3.18M | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $11.33M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $4.47M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $7.84M | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $10.88M | Mar 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 76.43M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 59.24M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 51.03M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 50,736 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 36.80M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 23,214 | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 15.64M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 9.54M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 57.63M | Mar 19, 2019 |
| FY2017 | Dec 31, 2016 | 42.70M | Mar 20, 2018 |